ArticleMedicina (Kaunas, Lithuania)2026
The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.
Canan Yıldız, Meltem Baykara, Hacer Demir, Ramazan Cosar, Sedat Yıldız, Beyza Unlu, Yaşar Culha, Duygu Ozaskin, Merve Kuday Özkan, Fariz Emrah Özkan and 1 more
Abstract read
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Canan YıldızDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0003-1834-7216 Meltem BaykaraDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0003-3291-8134 Hacer DemirDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.
Ramazan CosarDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0002-6363-2502 Sedat YıldızDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0002-3817-8934 Beyza UnluDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0002-8178-0277 Yaşar CulhaDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0002-0317-7552 Duygu OzaskinDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0009-0004-6376-8399 Merve Kuday ÖzkanDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0009-0005-2873-2945 Fariz Emrah ÖzkanDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0002-4347-0366 Çiğdem ÖzdemirDepartment of Medical Pathology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.ORCID 0000-0001-8500-0744 Funding
Türk Tıbbi Onkoloji Derneği 26.04.2024
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, ErbB-3AgedErbB ReceptorsFemaleHumansMaleMiddle AgedMutationPrognosisProtein Kinase InhibitorsRetrospective StudiesEGFR protein, humanERBB3 protein, humanErbB ReceptorsProtein Kinase InhibitorsReceptor, ErbB-3EGFR-resistanceHER3non-small cell lung cancer
Identifiers
PMID41901620
PMCPMC13028177
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390